LabCorp/ARCA biopharma GENETIC-AF Poster Selected for Presentation at the 18th Annual Scientific Meeting of the Heart Failure...
08 September 2014 - 10:30PM
Business Wire
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company
developing genetically-targeted therapies for cardiovascular
diseases, today announced that a joint Laboratory Corporation of
America® Holdings (LabCorp®) (NYSE:LH) and ARCA personalized
medicine abstract has been accepted for moderated poster
presentation at the 18th Annual Scientific Meeting of the Heart
Failure Society of America, being held September 14-17, 2014 in Las
Vegas, Nevada. The poster describes the genetic test that is being
used to select patients for GENETIC-AF, a Phase 2B/3 adaptive
design clinical trial. The GENETIC-AF trial will evaluate Gencaro™
(bucindolol hydrochloride) as a potential treatment for the
prevention of atrial fibrillation (AF) in patients with heart
failure and left ventricular dysfunction who also have a specific
genotype of the beta-1 adrenergic receptor (389 arginine
homozygous), which ARCA believes is present in approximately 50% of
the U.S. population. LabCorp is performing the genetic testing for
the GENETIC-AF trial.
Melissa Barhoover, Ph.D., IVD Regulatory Manager at LabCorp
Clinical Trials, and Christopher Dufton, Ph.D., Vice President,
Clinical Development at ARCA, are scheduled to present
“Personalized Medicine: Prospective Patient Selection Utilizing an
ADRB1 Genotype Assay in the GENETIC-AF Clinical Trial” during the
poster session Monday, September 15, 2014, 5:15 – 6:15 pm PT.
More information about the conference is available at:
http://www.hfsa.org/annual_meeting.asp.
About ARCA biopharma
ARCA is dedicated to developing genetically-targeted therapies
for cardiovascular diseases. The Company's lead product candidate,
Gencaro™ (bucindolol hydrochloride), is an investigational,
pharmacologically unique beta-blocker and mild vasodilator being
evaluated for atrial fibrillation in the Phase 2B/3 clinical trial
GENETIC-AF, which began enrolling patients in the second quarter of
2014. ARCA has identified common genetic variations that it
believes predict individual patient response to Gencaro, giving it
the potential to be the first genetically-targeted atrial
fibrillation prevention treatment. ARCA has a collaboration with
Medtronic, Inc. for support of the GENETIC-AF trial. For more
information please visit www.arcabiopharma.com.
Safe Harbor Statement
This press release and the anticipated poster presentation
contain "forward-looking statements" for purposes of the safe
harbor provided by the Private Securities Litigation Reform Act of
1995. These statements include, but are not limited to, statements
regarding, potential timing for patient enrollment in the
GENETIC-AF trial, the sufficiency of the Company’s capital to
support its operations, the potential for genetic variations to
predict individual patient response to Gencaro, Gencaro’s potential
to treat atrial fibrillation, future treatment options for patients
with atrial fibrillation, and the potential for Gencaro to be the
first genetically-targeted atrial fibrillation prevention
treatment. Such statements are based on management's current
expectations and involve risks and uncertainties. Actual results
and performance could differ materially from those projected in the
forward-looking statements as a result of many factors, including,
without limitation, the risks and uncertainties associated with:
the Company's financial resources and whether they will be
sufficient to meet the Company's business objectives and
operational requirements; results of earlier clinical trials may
not be confirmed in future trials, the protection and market
exclusivity provided by the Company’s intellectual property; risks
related to the drug discovery and the regulatory approval process;
and, the impact of competitive products and technological changes.
These and other factors are identified and described in more detail
in ARCA’s filings with the SEC, including without limitation the
Company’s annual report on Form 10-K for the year ended December
31, 2013, and subsequent filings. The Company disclaims any intent
or obligation to update these forward-looking statements.
Investor & Media Contact:ARCA biopharma, Inc.Derek
Cole, 720-940-2163derek.cole@arcabiopharma.com
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Apr 2024 to May 2024
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From May 2023 to May 2024